Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25

Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises the price target from $24 to $25.